From Code to Cures: Mark DePristo on the Zero-to-One Biotech Journey

Mark DePristo, former CEO of BigHat Biosciences, reveals why the best biotech innovation doesn't bolt on AI later but bakes it into research from day one. He shifts from scaling a clinical-stage antibody powerhouse to the nimble "zero-to-one" world of Ember AI Studios, where small teams leverage AI to solve overlooked deep-tech problems. Mark illustrates how embedding high-throughput experimental loops into design processes creates a rhythm that feels less like a lab experiment and more like a jazz band finding its collective, synchronized flow.